
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics is attractive because RAP-219 has already established proof of concept in bipolar mania with statistically significant efficacy and a differentiated tolerability profile, including placebo-parity adverse events, no serious adverse events, and low discontinuation rates. The company’s 3Q26 execution also improved confidence in its pipeline, as FOCUS 1/2 continued enrolling, the RAP-641 IND was cleared, and pro-forma cash rose to $815.4M after raising about $420.7M, extending runway to YE29. With pivotal and late-stage catalysts spanning 4Q26 to 2H27, plus potential read-through from bipolar data into epilepsy and chronic pain, the platform offers meaningful multi-indication upside beyond the current pipeline.
Bears say
Rapport Therapeutics is a clinical-stage biotechnology company with no commercialized products, making its valuation highly dependent on the success of RAP-219 and earlier-stage nAChR programs rather than recurring revenue or established cash flow. The bear case is driven by significant binary clinical risk, including potential trial misses in focal onset seizures and bipolar mania, alongside the possibility of unexpected safety or tolerability issues that could materially impair development prospects. Additional downside stems from clinical and regulatory delays, step-therapy positioning, competitive threats, and ongoing financing risk until cash flow positive, all of which could pressure the stock before any meaningful de-risking occurs.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Rapport Therapeutics Inc (RAPP) Forecast
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares